论文部分内容阅读
目的探讨SHP-1基因在多发性骨髓瘤中的表达及意义。方法用RT-PCR的方法对初治的69例多发性骨髓瘤患者和21例正常对照的骨髓进行SHP-1水平的监测。结果①SHP-1 mRNA在正常对照组中呈阳性表达,初治、无治疗反应组多发性骨髓瘤患者中SHP-1表达的阳性率与表达水平明显低于正常对照组(p<0.01)。缓解后SHP-1 mRNA的表达升高,但低于正常对照组(P<0.01)。②Ⅰ期、Ⅱ期、Ⅲ期多发性骨髓瘤之间SHP-1 mRNA的表达水平比较无统计学意义。③SHP-1表达阳性组缓解率(86.2%)明显高于表达阴性组(42.5%)(P<0.01)。结论 SHP-1基因可能参与了多发性骨髓瘤的发病,但发病机制不清楚,其发挥了负调节作用,它表达降低或缺失影响着多发性骨髓瘤的发生发展。SHP-1与多发性骨髓瘤的疗效预后有关,可能用来作为判断疗效预后的指标。
Objective To investigate the expression and significance of SHP-1 gene in multiple myeloma. Methods The SHP-1 levels in 69 newly diagnosed multiple myeloma patients and 21 normal controls were detected by RT-PCR. Results ① The expression of SHP-1 mRNA in normal control group was significantly higher than that in normal control group (P <0.01). The positive rate and expression level of SHP-1 in multiple myeloma patients were significantly lower than those in normal control group. After remission, the expression of SHP-1 mRNA increased but was lower than that of the normal control group (P <0.01). ② The expression of SHP-1 mRNA in stage I, II and III multiple myeloma was not statistically significant. ③ The remission rate of SHP-1 positive group (86.2%) was significantly higher than that of negative group (42.5%) (P <0.01). Conclusion SHP-1 gene may be involved in the pathogenesis of multiple myeloma. However, the pathogenesis of SHP-1 gene is unclear. SHP-1 gene may play a negative regulatory role. The expression of SHP-1 may affect the occurrence and development of multiple myeloma. SHP-1 is associated with the prognosis of multiple myeloma and may be used as an indicator of prognosis.